

**PHARMACY AND THERAPEUTICS COMMITTEE  
MEDICAID/CHIP MEETING MINUTES  
May 14, 2026**

*Attendance: Microsoft Teams Meeting  
Gary Bledsoe, Staff/Clinical Pharmacist; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Kristen DeSorte, Staff/Clinical Pharmacist; Danielle Dolores, Director Pharmacy Services; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Gia Ho, Pharmacy Resident; Samantha Jackson, Formulary Pharmacist; Ruth John, Staff/Clinical Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Sheenu Joseph, Staff/Clinical Pharmacist; Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Brandi Mahler, Supervisor Pharmacy Technicians; Hannah McCaffrey, Manager Pharmacy Regulations & Implementations; Michele McKenna, Staff/Clinical Pharmacist; Lisa Murray, Staff/Clinical Pharmacist; Claudia Pinketti, Staff/Clinical Pharmacist; Ryan Prager, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Kateryna Puia, Clinical Programs Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Staff/Clinical Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Tara Swartz, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist*

*Excused: Dr. Paul Aitken, Medical Director; Dr. Neal Demp, Community Behavior Health; Dr. Demian Elder, Medical Director; Hailey Fry, Centennial Pharmacy; Yelena Hedrick, Staff/Clinical Pharmacist; Jessica Hoang-Le, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health*

*Minutes taken by: Joana Iverson*

**I. Administrative Update**

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<b>Minutes Review/Approval</b>	<i>D. Dolores presented the minutes from the February 2026 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>
<b>Rebranding</b>	<i>D. Dolores presented the Medicaid and CHIP rebranding taking effect on June 1, 2026</i>	<i>Informational</i>	<i>D. Dolores</i>	


**II. Drug Formulary Review/Update**

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<b>2026 DHS Prior Authorization Criteria Review</b>	<p>The Committee reviewed Prior Authorization criteria and approved as presented.</p> <ul style="list-style-type: none"> <li>• Sickle Cell Anemia Agents</li> <li>• Sephience</li> </ul>	<p>The Committee approved as presented.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>
<b>2026 Formulary Removals</b>	<p>The Committee reviewed the 2026 Formulary Removals (non-par). The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Pimecrolimus 1% cream</li> <li>• Cromolyn spray 5.2/act</li> <li>• Phospholine solution 0.125% ophthalmic</li> </ul>	<p>The Committee approved as presented. The 2026 Formulary Removals (non-par) will be sent to PARP for approval.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>
<b>Quantity Limit Additions</b>	<p>The Committee reviewed the Quantity Limit Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Ozempic Tablet - 1 tablet/day</li> <li>• Wegovy tablet - 1 tablet/day</li> <li>• Zepbound Kwikpen - 2.4 mL/28 days</li> <li>• Zepbound solution vial - 2 mL/28 days</li> </ul>	<p>The Committee approved as presented. The Quantity Limit Additions will be sent to PARP for approval.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>
<b>III. Specialty Drug Additions</b>	<p>The Committee reviewed the Specialty Drug Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> <li>• Anzupgo 2% cream</li> <li>• Aqvesme 100mg tablet</li> <li>• Avlayah 150mg injection</li> <li>• Brinsupri 10mg, 25mg tablet</li> <li>• Cablivi 11mg kit</li> <li>• Empavelli 1080 injection</li> <li>• Exdensur 100mg/mL injection</li> <li>• Exdensur 100mg/mL injection</li> <li>• Icotyde 200mg tablet</li> <li>• Lifyorli 125mg, 150mg capsule</li> <li>• Lunsumio 1mg/mL, 5mg/0.5mL, 30mg/30mL, 45mg/mL injection</li> <li>• Myqorzo 5mg, 10mg, 15mg, 20mg tablet</li> <li>• Nintedanib 100mg, 150mg capsule</li> <li>• Pomalidomide 1mg, 2mg, 3mg, 4mg capsule</li> <li>• Rubraca 200mg, 250mg, 300mg tablet</li> <li>• Rybrevant Faspro 1600-20000mg-unit/10mL, 2240-28000mg-unit/14mL, 2400-30000mg-unit/15mL, 3520-44000mg-unit/22mL injection</li> <li>• Tofidence 400mg/20mL injection</li> <li>• Wainua 45mg/0.8mL injection</li> <li>• Xtrenbo 120mg/1.7mL injection</li> <li>• Yuwiwel 1.3mg, 2.8mg, 5.5mg injection</li> </ul>	<p>The Committee approved as presented. The Specialty Drug Additions will be sent to PARP for approval.</p>	<p>F. Vaisberg</p>	<p>Resolved</p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> <li>Zycubo 2.9mg injection</li> </ul>			
<b>IV. New Drug Review</b>	<p>G. Ho presented the New Drug Review list to the Committee. The following new products were reviewed and will be kept as non-formulary:</p> <ul style="list-style-type: none"> <li>Foundayo (orforglipron) Tablets</li> <li>Ponlimsi (denosumab-adet) Injection</li> <li>Awiqli (insulin icodec-abae) Injection</li> <li>Kresladi (marnetegragene autotemcel) Suspension for Intravenous Infusion</li> <li>Lifyorli (relacorilant) Capsules</li> <li>Avlayah (tividenofusp alfa-eknm) Lyophilized Powder for Injection</li> <li>Lynavoy (linerixibat) Tablets</li> <li>Icotyde (icotrokinra hydrochloride) Tablets</li> <li>Yuviwel (navepegritide) Lyophilized Powder for Injection - formerly TransCon CNP</li> <li>Desmoda (desmopressin acetate) Oral Solution - formerly ET-600</li> <li>Loargys (pegzilarginase-nbln) Injection</li> <li>Bysanti (milsaperidone) Tablets</li> <li>Adquey (difamilast) Ointment</li> </ul>	The Committee approved the New Drug Review as presented and recommended.	G. Ho	Resolved

**V. Adjournment**

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held August 2026.



5/27/2026

\_\_\_\_\_  
Danielle Dolores, Director of Pharmacy Services

\_\_\_\_\_  
Date